A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

Trial Details

NCT ID
NCT05519085
Phase
PHASE3
Sponsor
Celgene
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • mezigdomide
  • Pomalidomide
  • Bortezomib
  • Dexamethasone
Locations (sample)
  • Los Alamitos, California, United States|33.80307,-118.07256
  • San Diego, California, United States|32.71571,-117.16472
  • West Hollywood, California, United States|34.09001,-118.36174
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Farmington, Connecticut, United States|41.71982,-72.83204

Key Eligibility Criteria

  • \- Participant has documented diagnosis of MM and measurable disease, defined as any of the following:.
  • i) M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or.
  • ii) M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP).
  • iii) For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels \> 100 mg/L (10 mg/dL) involved light chain …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →